(Q40045704)

16 September 2017

title

Correlation between the in vitro ATP-based chemosensitivity assay and HER2/neu expression in women with breast cancer (English)

1 reference

16 September 2017

S U Woo

1

1 reference

16 September 2017

J W Bae

2

1 reference

16 September 2017

H G Kim

3

1 reference

16 September 2017

S H Choi

4

1 reference

16 September 2017

D H Kang

5

1 reference

16 September 2017

J B Lee

6

1 reference

16 September 2017

B W Koo

7

1 reference

16 September 2017

publication date

1 November 2007

1 reference

Journal of International Medical Research

16 September 2017

published in

1 reference

16 September 2017

volume

35

1 reference

16 September 2017

issue

6

1 reference

16 September 2017

page(s)

753-761

1 reference

A feasibility study of the MTT assay for chemosensitivity testing in ovarian malignancy

16 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F147323000703500603

Docetaxel compared with sequential methotrexate and 5-fluorouracil in patients with advanced breast cancer after anthracycline failure: a randomised phase III study with crossover on progression by the Scandinavian Breast Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323000703500603

HER-2/neu in node-negative breast cancer: prognostic significance of overexpression influenced by the presence of in situ carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323000703500603

Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323000703500603

Review of the efficacy of individualized chemotherapy selected by in vitro drug sensitivity testing for patients with cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323000703500603

A feasibility study of adenosine triphosphate-based chemotherapy response assay (ATP-CRA) as a chemosensitivity test for lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323000703500603

Adjuvant systemic therapy and survival after breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323000703500603

Predictive value of the ATP chemosensitivity assay in epithelial ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323000703500603

Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323000703500603

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323000703500603

HER2 and responsiveness of breast cancer to adjuvant chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323000703500603

Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323000703500603

Prediction of chemotherapeutic response by collagen gel droplet embedded culture-drug sensitivity test in human breast cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F147323000703500603

10.1177/147323000703500603

21 January 2018

Identifiers

DOI

1 reference

16 September 2017

1 reference